Gilead Q4 2022 rev $7.4B, EPS $1.30; ex-Veklury sales +9%; FY 2023 guidance $26.0-26.5B product sales

GILEAD SCIENCES, INC.

2022-FY EPS reported $3.64 revenue$27,281,000,000

Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.
GAAP diluted EPS Q4 $1.30 vs $0.30; non-GAAP $1.67 vs $0.69.
FY 2022 Biktarvy sales $10.4B (+20%); Trodelvy $680M (+79%); Cell Therapy $1.5B (+68%).
FY 2023 guidance: product sales $26.0-26.5B; GAAP EPS $5.30-5.70; non-GAAP EPS $6.60-7.00.
Q4 operating cash flow $2.6B; dividends $916M; share repurchases $791M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 2, 2023 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.